CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenue
Diagnostic testing service	$ 3,426	$ 72,187	$ 37,425	$ 361,905
Product sales	0	4,410	0	223,440
Total Revenue	3,426	76,597	37,425	585,345
Cost of Revenue
Diagnostic testing service	0	25,938	0	75,893
Product sales	0	0	0	238,669
Total Cost of Revenue	0	25,938	0	314,562
Gross Profit	3,426	50,659	37,425	270,783
Selling expenses	282,374	373,418	743,597	965,383
Research and development expenses	923,169	321,111	1,856,439	731,258
General and administrative expenses	2,043,138	2,858,027	6,280,102	6,600,819
Total operating expenses	3,248,681	3,552,556	8,880,138	8,297,460
Operating Loss	(3,245,255)	(3,501,897)	(8,842,713)	(8,026,677)
Interest income	11	53	154	53
Interest expense	151	1	2,343	360
Loss before Income Taxes	(3,245,395)	(3,501,845)	(8,844,902)	(8,026,984)
Income Taxes	0	0	0	0
Net Loss	$ (3,245,395)	$ (3,501,845)	$ (8,844,902)	$ (8,026,984)
Loss per common share - basic and diluted (in dollars per share)	$ (0.13)	$ (0.22)	$ (0.37)	$ (0.55)
Weighted average shares outstanding, basic & diluted (in shares)	24,537,379	15,830,033	23,860,843	14,697,221